showed a trendp = 0.058
However, in the Lenvatinib + surgery group (lenvatinib alone), the high-risk group showed a trend towards better DFS prognosis (log-rank p = 0.058, Fig. 6 C), while no difference was observed in the lenvatinib + TACE/TAI + surgery group (lenvatinib combined) (Fig. 6 F).